Main > ONCOLOGY (**) > Lung>NSCLC>Non-Squamous>MET or R*** > Treatment > CH. R. Brand BevacizuMAb+

---

CH. R. Brand BevacizuMAb+'s subsections
(*) EU>Approval>Date: 2016. 06.08.
+Erlotinib
>with EGFR-Activating Mutations
Company
PR Web-Site
TradeMark (BevacizuMAb)
TradeMark (Erlotinib)
UpDate: 2016. 06.08.

CH. R. Brand BevacizuMAb+'s products
This section has no products